ProQR nominates Boehringer Ingelheim executive to board of directors

ProQR Therapeutics N.V. (NASDAQ: PRQR) announced the nomination of Dr. Lykke Hinsch Gylvin to its board of directors, according to a company statement.

Dr. Hinsch Gylvin currently serves as Chief Medical Officer and Head of Global Medicine at Boehringer Ingelberg, where she leads global medical and clinical development across multiple therapeutic areas including oncology, cardiometabolic diseases, immunology, CNS, and rare diseases.

The nomination requires shareholder approval at ProQR's upcoming Annual General Meeting of Shareholders. If appointed, Dr. Hinsch Gylvin would serve as an independent non-executive director.

Dr. Hinsch Gylvin brings more than 20 years of pharmaceutical leadership experience spanning all phases of drug development. Before joining Boehringer Ingelheim, she held senior leadership positions at Novartis and AstraZeneca, leading global medical and development strategies. She also worked at Roche, Novo Nordisk, and Lundbeck in clinical development, regulatory strategy, and global medical affairs roles.

"Her extensive experience in global drug development and broad perspective across therapeutic areas will complement the expertise of our Board," said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics.

Dr. Hinsch Gylvin holds an MD from the University of Copenhagen and an Executive MBA from SBS Swiss Business School.

ProQR is a clinical-stage company developing RNA therapies based on its Axiomer RNA editing technology platform.

You May Also Be Interested In

• IQM names Barbara Venneman to board ahead of planned Nasdaq listing
• Healthcare Triangle completes $3.6 million convertible note offering
• Medtronic completes $550 million Scientia Vascular acquisition